Exosome Diagnostics reels in $17.6M for liquid biopsy development

Exosome Diagnostics CEO Thomas McLain

Exosome Diagnostics raked in $17.6 million in a second round of Series B financing, bringing the total amount raised to $44.7 million. The company plans to use the funds to support the launch of a few of its products, including two blood-based lung cancer liquid biopsies, a urine-based prostate cancer liquid biopsy and a solid tumor panel. Exosome will also funnel the cash toward development and a projected 2016 launch for its new solid tumor panel as well as to create tests for neurodegenerative diseases, the company said in a statement. "These funds also will enable us to drive our next generation of cancer diagnostics and, importantly, begin expanding into other disease areas, potentially bringing the benefits of exosome-based molecular diagnostics to patients across a broad spectrum of indications and medical needs," CEO Thomas McLain said in a statement. Statement

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.